RIGI and nasopharyngeal carcinoma: Given RIG-I antiviral activity and ligands-mediated antitumor responses depend on functional RIG-I expression, this treatment should be a careful assessment especially for EBV-positive NPC, because RIG-I might contribute to NPC development (34) or RIG-I is destroyed by EBV and could not be induced by IFN-α as revealed in this study.